The multicenter NATURE trial randomized 154 patients to evaluate the enVast Coronary Clot Retriever as an adjunct to standard care. Principal investigator Prof. Marco Valgimigli reported that the device, which uses proprietary Drop Zone technology to capture thrombi, successfully limited myocardial injury compared to conventional intervention alone. The study utilized CK-MB area-under-the-curve metrics to confirm the reduction in damage, supported by cardiac magnetic resonance imaging showing a 25% relative improvement in infarct size at three days.
Vesalio’s enVast Retriever Reduces Heart Damage in STEMI Patients
Patients undergoing primary percutaneous coronary intervention for heart attacks saw a 26% reduction in infarct size when treated with the enVast clot retrieval device. Results from the NATURE clinical trial, presented at the 2026 ESC Congress in Munich, suggest mechanical thrombectomy offers a superior outcome for complex large thrombus cases.
Beyond efficacy, the trial highlighted a robust safety profile for the intervention. The enVast arm recorded zero deaths and zero strokes within the 30-day follow-up period, contrasting with a 2.6% mortality rate and 1.3% stroke incidence in the control group. Major adverse cardiovascular events also tracked lower for those treated with the device, at 1.3% versus 3.8%. These findings build on earlier first-in-human studies, providing clinical validation for the selective use of mechanical thrombectomy in patients facing high thrombus burden during ST-segment elevation myocardial infarction.
Comments (0)
No comments yet. Be the first!